Am J Physiol Gastrointest Liver Physiol April 2021 PMID 33439105

Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.

Yoichi Sato, Jiahe Qiu, Takuo Hirose, Takahiro Miura, Yasunori Sato, Masahiro Kohzuki, Osamu Ito

Full text PDF Download social card

Mentions

Peak: 2 in Apr 2022

across 2 sources since Jan 2021

Extended reach

346,874

potential audience

Total likes

11,124

Video views

335,306

Mentions per month

Jan 2021 – Aug 2025

Where it's discussed

X / Twitter5 posts
YouTube3 videos

AI synopsis

What people are saying

The overall tone demonstrates a cautious optimism, with mentions of metformin reducing liver cyst formation and fibrosis, and references to signaling pathways like AMPK and mTOR, indicating some participants engage with scientific details. Words like 'potential' and 'new in' highlight the importance of the research while maintaining a focus on its promising nature.

AgreementModerate agreement

Most discussions acknowledge the positive findings about metformin's potential for treating polycystic liver disease, showing general agreement.

InterestModerate interest

The discussions indicate moderate curiosity, mentioning the therapeutic implications and basic mechanisms.

EngagementModerate engagement

Participants reference specific pathways like AMPK and mTOR, suggesting some engagement with the scientific content.

ImpactModerate impact

The dialogue hints at recognition of the study's significance, considering it a promising step towards new treatments.

Abstract in brief

Metformin can slow down liver cyst growth and fibrosis in a rat model of polycystic liver disease by activating AMPK and inhibiting pathways related to cell proliferation and fibrosis.
The study found that metformin treatment reduced cyst formation, cell proliferation, and fibrosis without affecting overall body or liver weight, and it worked by altering specific signaling pathways like mTOR and ERK.
These findings suggest that metformin, commonly known for diabetes treatment, could be a potential therapy for managing polycystic liver disease by targeting cellular growth and fibrotic processes.]

Read the full abstract